Skip to main content
. 2021 Apr 29;11:635537. doi: 10.3389/fonc.2021.635537

Table 3.

Comparison of clinical baseline characteristics between APA-GI patients with HA and non-HA.

Characteristic non-HA HA P-value
Age(y), median(IQR) 61.0 (50.0–70.5) 63.0 (58.0–71.8) 0.247
Sex, Male/Female (Male%) 22/19 (53.7) 28/4 (87.5) 0.002
Primary site, n (%) 0.321
Stomach 33 (80.5) 27 (84.4)
Large intestine 7 (17.1) 3 (9.4)
Small intestine 1 (2.4) 0 (0.0)
Esophagus 0 (0.0) 1 (3.1)
Multiple primary sites 0 (0.0) 1 (3.1)
Tumor size(cm), median(IQR) 4.5 (3.5–5.3) 5.0 (3.0–6.0) 0.668
Differentiation, n (%) 0.007
Highly differentiated 0 (0.0) 0 (0.0)
Moderately differentiated 17 (41.5) 5 (15.6)
Poorly differentiated 21 (51.2) 27 (84.4)
Default 3 (7.3) 0 (0.0)
pT, n (%) 0.913
1 3 (7.3) 2 (6.3)
2 6 (14.6) 4 (12.5)
3 5 (12.2) 6 (18.8)
4 27 (65.9) 20 (62.5)
pN, n (%) 0.825
0 8 (19.5) 7 (21.9)
1 6 (14.6) 7 (21.9)
2-3 25 (61.0) 17 (53.1)
Default 2 (4.9) 1 (3.1)
TNM staging, n (%) 0.514
I-III 31 (75.6) 22 (68.8)
IV 10 (24.4) 10 (31.3)
Liver metastasis 0.084
Yes 9 (22.0) 13 (40.6)
No 32 (78.0) 19 (59.4)
Extrahepatic metastasis 0.756
Yes 22 (53.7) 16 (50.0)
No 19 (46.3) 16 (50.0)
Lymphatic or/and blood vessel invasion 0.269
Yes 19 (46.3) 19 (59.4)
No 22 (53.7) 13 (40.6)
Nerve invasion 0.486
Yes 11 (26.8) 11 (34.4)
No 30 (73.2) 21 (65.6)

HA, hepatic adenocarcinoma; non-HA, non-hepatic adenocarcinoma.